NABOTA 200ui 1Vial
$139.00
Description
Nabota Botulinum toxin type A is indicated for the temporary improvement in the appearance of the upper respiratory tract (forehead lines, crow’s feet and forehead lines) in adults. Botulinum toxin type A (Nabota) is indicated for the prevention of headaches in adults with chronic migraine.
Specifications
- Main Ingredient: Botulinum Toxin Type A
- Manufacturer: DAEWOONG PHARMACEUTICAL CO. LTD
- Drug Class:
- Generic Name:
- Package Contents: 200u 1 Vial
- Storage Requirements: Cool Temperature (2℃~8℃)
- Main Usage:
About the Brand
NABOTA
Here to help
Questions about ordering, delivery or products? You can email our team here or call now at 1-800-630-9757 and be connected with your dedicated Account Manager
Related Products
Related Articles
Cytocare: Anti-Aging Innovations in Cosmetology
In advanced cosmetology, Cytocare has emerged as a groundbreaking anti-aging treatment. Developed to combat signs…
Belotero Filler: The Art of Dermal Fillers
Belotero dermal fillers have become a key player in aesthetic medicine, renowned for their ability…
The Science Behind Jalupro: How It Stimulates Collagen Production
Collagen is essential for maintaining youthful and healthy skin, but its natural production decreases as…
AESTHEFILL Injection: Skin Collagen Stimulators
Collagen stimulators like Aesthefill are redefining how we approach skin rejuvenation. Unlike traditional fillers that…
Ella Birth Control vs. Other Emergency Contraceptives: Key Comparisons
Emergency contraception is a critical aspect of reproductive healthcare, offering women a last line of…
Introduction to Croma Philart: What You Need to Know
As medical practitioners, staying informed about innovative treatments is crucial to offering patients the best…
ALIAXIN: A Detailed Introduction to Its Uses and Benefits
Aliaxin is a distinguished brand of dermal fillers that has become an integral tool in…
Intraline and Its Applications in Anti-Aging Treatments: Key Advantages
The demand for effective and safe anti-aging treatments continues to rise in the ever-evolving field…